These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1906 related articles for article (PubMed ID: 28968163)

  • 1. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
    Goetz MP; Toi M; Campone M; Sohn J; Paluch-Shimon S; Huober J; Park IH; Trédan O; Chen SC; Manso L; Freedman OC; Garnica Jaliffe G; Forrester T; Frenzel M; Barriga S; Smith IC; Bourayou N; Di Leo A
    J Clin Oncol; 2017 Nov; 35(32):3638-3646. PubMed ID: 28968163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.
    Goetz MP; Toi M; Huober J; Sohn J; Trédan O; Park IH; Campone M; Chen SC; Manso LM; Paluch-Shimon S; Freedman OC; O'Shaughnessy J; Pivot X; Tolaney SM; Hurvitz SA; Llombart-Cussac A; André V; Saha A; van Hal G; Shahir A; Iwata H; Johnston SRD
    Ann Oncol; 2024 Aug; 35(8):718-727. PubMed ID: 38729566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
    Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A
    J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
    Toi M; Inoue K; Masuda N; Iwata H; Sohn J; Hae Park I; Im SA; Chen SC; Enatsu S; Turner PK; André VAM; Hardebeck MC; Sakaguchi S; Goetz MP; Sledge GW
    Cancer Sci; 2021 Jun; 112(6):2381-2392. PubMed ID: 33686753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
    Goetz MP; Martin M; Tokunaga E; Park IH; Huober J; Toi M; Stoffregen C; Shekarriz S; Andre V; Gainford MC; Price GL; Johnston S
    Oncologist; 2020 Sep; 25(9):e1346-e1354. PubMed ID: 32536013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
    Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
    Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Blackwell KL; André F; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Petrakova K; Hart LL; Villanueva C; Chan A; Jakobsen E; Nusch A; Burdaeva O; Grischke EM; Alba E; Wist E; Marschner N; Favret AM; Yardley D; Bachelot T; Tseng LM; Blau S; Xuan F; Souami F; Miller M; Germa C; Hirawat S; O'Shaughnessy J
    N Engl J Med; 2016 Nov; 375(18):1738-1748. PubMed ID: 27717303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
    Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
    Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
    Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Conte P; Lu Y; Barriga S; Hurt K; Frenzel M; Johnston S; Llombart-Cussac A
    JAMA Oncol; 2020 Jan; 6(1):116-124. PubMed ID: 31563959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
    Inoue K; Masuda N; Iwata H; Takahashi M; Ito Y; Miyoshi Y; Nakayama T; Mukai H; van der Walt JS; Mori J; Sakaguchi S; Kawaguchi T; Tanizawa Y; Llombart-Cussac A; Sledge GW; Toi M
    Breast Cancer; 2021 Sep; 28(5):1038-1050. PubMed ID: 33797023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
    Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
    Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
    Takahashi M; Tokunaga E; Mori J; Tanizawa Y; van der Walt JS; Kawaguchi T; Goetz MP; Toi M
    Breast Cancer; 2022 Jan; 29(1):174-184. PubMed ID: 34661821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.
    Goetz MP; Hamilton EP; Campone M; Hurvitz SA; Cortes J; Johnston S; Llombart-Cussac A; Kaufman PA; Toi M; Jerusalem G; Graham H; Wang H; Jansen VM; Litchfield LM; Martin M
    Clin Cancer Res; 2024 May; 30(10):2233-2244. PubMed ID: 37889120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
    Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
    Sonke GS; Hart LL; Campone M; Erdkamp F; Janni W; Verma S; Villanueva C; Jakobsen E; Alba E; Wist E; Favret AM; Bachelot T; Hegg R; Wheatley-Price P; Souami F; Sutradhar S; Miller M; Germa C; Burris HA
    Breast Cancer Res Treat; 2018 Feb; 167(3):659-669. PubMed ID: 29058175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.
    Johnston S; Martin M; Di Leo A; Im SA; Awada A; Forrester T; Frenzel M; Hardebeck MC; Cox J; Barriga S; Toi M; Iwata H; Goetz MP
    NPJ Breast Cancer; 2019; 5():5. PubMed ID: 30675515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study.
    Zhang QY; Sun T; Yin YM; Li HP; Yan M; Tong ZS; Oppermann CP; Liu YP; Costa R; Li M; Cheng Y; Ouyang QC; Chen X; Liao N; Wu XH; Wang XJ; Feng JF; Hegg R; Kanakasetty GB; Coccia-Portugal MA; Han RB; Lu Y; Chi HD; Jiang ZF; Hu XC
    Ther Adv Med Oncol; 2020; 12():1758835920963925. PubMed ID: 33149768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 96.